|Articles|October 30, 2018

Biogen and Samsung Bioepis Launch Humira Biosimilar in Europe

The companies announced the European launch of Imraldi (adalimumab), a biosimilar referencing AbbVie’s blockbuster Humira (adalimumab).

Biogen and Samsung Bioepis announced the European launch of Imraldi (adalimumab), a biosimilar referencing AbbVie’s blockbuster biologic, Humira (adalimumab), in an Oct. 17, 2018 press release. AbbVie’s Humira is that company’s top-selling product with $18.4 billion in 2017 sales.  

Internal server error